Skip to content
Screener

Total Equity at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$22.32B+28.0%
Amgen logo
AmgenAMGN
$11.69B+57.4%
Gilead Sciences logo
Gilead SciencesGILD
$11.83B-39.9%
Exelixis logo
ExelixisEXEL
$1.84B-9.3%
IDEAYA Biosciences, Inc. logo
IDEAYA Biosciences, Inc.IDYA
$937.27M-8.5%
Erasca, Inc. logo
Erasca, Inc.ERAS
$393.53M-1.5%

Other financials

Income statement

See full
Revenue--100%
Operating income-$48.8M-14.7%
Net income-$45.5M-14.1%
EPS (diluted)-$0.32+11.1%

Balance sheet

See full
Cash & equivalents$160.0M+162%
Total debt$32.8M-11.3%
Total assets$435.8M+58.9%

Cash flow

See full
Operating cash flow-$44.4M-6.4%
CapEx-$2.0K-104%
Free cash flow-$44.4M-6.3%

Valuation

See full
Market cap$4.72B+570%
Enterprise value$4.59B+558%
P/S82.9×+53.9×

Profitability

See full
Operating margin-206.2%-61.0pp
Net margin-188.2%-55.4pp
FCF margin-250.1%-49.4pp

Returns & leverage

See full
Return on equity-38.4%-10.5pp
Debt / equity0.1×-0.1×
Current ratio27.4×+21.1×

Where this comes from

Reported directly by Tango Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:StockholdersEquity.

The source filing: Tango Therapeutics’s 10-Q, filed May 13, 2026.

Filed
May 13, 2026, 4:15 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-221656
Line itemMarch 31, 2026December 31, 2025
Preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively
Stockholders' equity:
Common stock, $0.001 par value; 400,000,000 and 200,000,000 shares authorized at March 31, 2026 and December 31, 2025, respectively; 144,162,543 and 135,940,454 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively144136
Additional paid-in capital1,040,143948,971
Accumulated other comprehensive (loss) income(115)224
Accumulated deficit(648,666)(603,152)
Total stockholders’ equity391,506346,179
Total liabilities and stockholders’ equity$435,792$398,690

Item 1. Financial Statements.

FAQ

What is Tango Therapeutics's total equity?
Tango Therapeutics (TNGX) reported total equity of $391.51M in Q1 2026.
How has Tango Therapeutics's total equity changed year-over-year?
Tango Therapeutics's total equity increased by 134.8% year-over-year, from $166.76M to $391.51M.
What is the long-term trend for Tango Therapeutics's total equity?
Over 5 years (2020 to 2025), Tango Therapeutics's total equity has grown at a 55.1% compound annual growth rate (CAGR), from $38.6M to $346.18M.
What does total equity mean?
Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.

Ask your AI about Tango Therapeutics's total equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude